Navigation Links
Cellular Therapy and Cord Blood 2013 Market Report
Date:3/25/2013

Dublin, Ireland (PRWEB) March 25, 2013

This latest report analyzes clinical trial trends and the evolution of several therapeutics areas within cellular therapy [orthopedic, skin/wound care, cardiovascular, and CNS disorders] and presents the current status of every single program within the preclinical through the various clinical trial phases and onto commercialization. We also present the breakout of clinical trials in the bona fide cellular therapy sector with respect to geographic breakout, breakout by type of cells utilized, and disease classes interrogated.

Select Biosciences has also provided a detailed quantitative analysis of the cord blood field as it is rapidly evolving. The report's coverage provides hard numbers on sizes of the various registries, the TNC breakouts of banked units, detailed cost breakouts for banking as well as HSCTs utilizing cord blood. Furthermore, given the author's global footprint, they've been able to compare the EU and US markets side-by-side in this analysis.

ATMP regulatory guidelines governing the marketing authorization of cellular therapeutics in the European Union are also given. Details on the statute as well as implications to companies seeking to navigate this space are provided.

Presented in this Report

  • Regenerative Medicine and Stem Cell Research Activity in the US
  • Sales of Commercial Products and Services in Stem Cell/Regenerative Medicine Sectors
  • Breakout of Spending by Companies in the Cellular Therapy/Regenerative Medicine Space
  • Breakout of Spending by Product Platforms in Various Spaces
  • Autologous vs. Allogeneic Business Models in the Cellular Therapy Space
  • Autologous vs. Allogeneic Cellular Therapy: Industry SWOT
  • Adult Stem Cell Therapy Quantitative Market Forecast
  • Cellular Therapy Product Pipeline
  • Clinical Trials Quantitative Metrics and Detailed Breakout by Phase, Cell Type, Therapeutic Areas Addressed, Geography
  • HSCTs Performed in the EU: Percent Breakout by Disease Classes Addressed
  • Indications for HSCTs in North America: Disease Classes Addressed, Age of Recipients, Types of HSCs Utilized, Classes of Transplant Inoculum
  • Cost Analyses of HSCTs in the EU vs. US Markets
  • Cord Blood Banking Quantitative Market Metrics
  • Growth of BM, PBL, and CB Units Worldwide in Public Banks and Registries, Segmented by Country
  • Cord Blood Transplantation Trends: Age of Recipient, Disease Classes Addressed
  • EU and US Cord Blood Transplantation Detailed Cost Breakouts
  • EU ATMP Regulation Detailed Analysis
  • Stem Cells Worldwide Publications Analysis

For more information visit http://www.researchandmarkets.com/research/5hw5xw/cellular_therapy

Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Research and Markets
Laura Wood, Senior Manager.
press(at)researchandmarkets(dot)com
Phone: +35314151241
Sector: Biotechnology

Read the full story at http://www.prweb.com/releases/2013/3/prweb10560183.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Cellular Dynamics and Coriell Institute for Medical Research Awarded Multi-Million Dollar Grants from California Institute for Regenerative Medicine to Manufacture and Bank Stem Cell Lines
2. Cellular Biomedicine Group Appoints Dr. Jianping Dai to the Board of Directors
3. Cellular Biomedicine Group President Presents Keynote Address at New York Stem Cell Summit
4. Cellular Biomedicine Group Announces ISO 9001:2008 Certification and ISO-14644 Cleanroom Certification
5. Cellular Therapy Market and Cord Blood Market 2013 Industry Research Report: MarketResearchReports.Biz
6. EastBridge Investment Group Announces Completion of its Merger with Cellular Biomedicine Group - Shareholder Conference Call to be held February 8th
7. Childhood Obesity Linked to Increased Risk of Hepatocellular Carcinoma in Adulthood
8. Proteins shine a brighter light on cellular processes
9. Van Andel Research Institute Study Provides New Details of Fundamental Cellular Process
10. Cellular Dynamics Announces Commercial Launch of iCell® Neurons for Neuroscience Drug Discovery
11. SoundMindz TM Releases ‘Anti-Anxiety TM’ Mobile App - A Complete Stress Therapy Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... China Biologic Products, Inc. (NASDAQ: CBPO) ("China Biologic" or the ... today announced its financial results for the fourth quarter and ... Financial Highlights Total sales in the ... or increased by 13.6% in USD terms to $77.6 million ... Gross profit increased by 13.3% to $46.8 million ...
(Date:2/23/2017)... and NEW YORK , ... Lumeon , a leading digital health company, ... a provider of telemedicine and remote patient monitoring, ... for telemedicine reimbursements.  DN Telehealth ... patients, in real-time, extending consultations beyond a physical ...
(Date:2/23/2017)... TORONTO , Feb. 23, 2017 /PRNewswire/ - The ... Institute for Cancer Research (OICR) are pleased to report ... Series A financing, with Johnson & Johnson Innovation – ... investors include venture groups HealthCap, TPG Biotechnology Partners, and ... ...
(Date:2/23/2017)... SEATTLE , Feb. 23, 2017  Seattle,s upscale Capitol ... like a strange place for a head lice treatment salon ... nestled between a Tuscan restaurant and a French bistro on ... it,s perfect. "We aren,t just any old lice clinic, we ... to feel comfortable, and release some of the stigma associated ...
Breaking Biology Technology:
(Date:2/8/2017)... 2017  Aware, Inc. (NASDAQ: AWRE ), a ... results for its quarter and year ended December 31, 2016. ... was $3.9 million compared to $6.9 million in the same ... 2016 was $0.6 million compared to $2.6 million in the ... of 2016 was $0.5 million, or $0.02 per diluted share, ...
(Date:2/7/2017)... , Feb. 7, 2017 Zimmer Biomet ... in musculoskeletal healthcare, will present at the LEERINK Partners ... York Palace Hotel on Wednesday, February 15, 2017 at ... webcast of the presentation can be accessed at ... following the conference via Zimmer Biomet,s Investor Relations website ...
(Date:2/2/2017)... 2017   TapImmune, Inc. (NASDAQ: ... in the development of innovative peptide and gene-based ... and metastatic disease, announced today it has successfully ... a second clinical lot of TPIV 200, the ... The manufactured vaccine product will be used to ...
Breaking Biology News(10 mins):